CureVac N.V.
XETRA: 5CV.DE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Deutsche Börse
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alexander Zehnder
- Employees
- 825
- Headquarters
- Tübingen, Germany
- IPO year
- 2020
- Market cap
- €879.5M
- Website
- https://www.curevac.com
Loading 5CV…
Loading profile data…Frequently asked questions about 5CV
What does CureVac N.V. (5CV.DE) do?
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which...
Where does 5CV.DE trade?
CureVac N.V. (5CV.DE) trades on the Deutsche Börse.
What sector is 5CV.DE in?
CureVac N.V. (5CV.DE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CureVac N.V.?
Alexander Zehnder is the chief executive officer of CureVac N.V. (5CV.DE).
Where is CureVac N.V. headquartered?
CureVac N.V. is headquartered in Germany.
Does 5CV.DE pay a dividend?
CureVac N.V. (5CV.DE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 5CV.DE go public?
CureVac N.V. (5CV.DE) completed its initial public offering in 2020.